-
Celebrating Chinese Doctor’s Day!
On August 19th, we honor the incredible dedication and compassion of doctors who work tirelessly to safeguard our health. Let’s take a moment to appreciate their unwavering commitment to preserving…
-
Building a Health Defense Line, Focusing on China Anemia Day on August 18th: Caring for the Source of Life, Starting with Understanding Anemia
Understanding Anemia: The Invisible Health Challenge Anemia, in simple terms, refers to a reduction in the peripheral blood red blood cell (RBC) count below the normal range, a common clinical…
-
Cutting-edge Bi-monthly: July Literature Digest (Part 1)
01 Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study Recent studies indicate that BCR::ABL1 may affect multiple hematopoietic lineages in Philadelphia chromosome-positive acute lymphoblastic leukemia…
-
Dr. Zefei Jiang: Highlights, Innovations, and Reflections | 2024 Breast Cancer Summer Forum · Northern Salon
01 Oncology Frontier: As the chairman of the “2024 Breast Cancer Summer Forum · Northern Salon,” could you introduce the setup and highlights of the conference? Dr. Zefei Jiang: The…
-
ESMO 2024丨Key Research in Hematological Malignancies (Mini oral)
01 Abstract Number：799MO The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis 02 Abstract Number：800MO First Report of BCL-2 Inhibitor TQB3909…
-
Dr. Nicolaus Kroger: New Perspectives on Myelofibrosis Treatment – Focusing on Post-Transplant Management and Minimal Residual Disease Monitoring
Oncology Frontier-Hematology Frontier：In the treatment of myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the potentially curative therapy. What do you think about optimizing transplant strategies to improve long-term…
-
Advancing Early-Stage Breast Cancer Monitoring with ctDNA Structural Variant Detection
A recent study published in Clinical Cancer Research (Jan 9, 2025) highlights the potential of structural variant (SV)-based circulating tumor DNA (ctDNA) detection in early-stage breast cancer (EBC). Unlike traditional…
-
Phase 3 EMBER-3 Trial: Imlunestrant in Advanced Breast Cancer
A study published in NEJM on December 11, 2024, led by Komal L. Jhaveri and colleagues, evaluated Imlunestrant, a next-generation oral selective estrogen receptor (ER) degrader, in ER-positive, HER2-negative advanced…
Connecting Medical Expertise through Media